Endocyte Announces Presentations at the 254th American Chemical Society National Meeting & Exposition
August 16 2017 - 08:00AM
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small
molecule drug conjugates (SMDCs) and companion imaging agents for
personalized therapy, today announced that four posters will be
presented by Endocyte scientists at the 254th American Chemical
Society (ACS) National Meeting & Exposition being held in
Washington, DC, August 20-24, 2017.
“Our presentations will focus on the application of novel
chemistries toward the synthesis of SMDCs for the treatment of
cancer and inflammation, including EC2629, our folate-targeted PBD
agent that simultaneously targets cancer cells and the tumor
associated macrophages (TAMS) for which we recently filed an IND,”
said Iontcho Vlahov, Ph.D., vice president of discovery chemistry.
“In our presentations, we will detail the syntheses of folate
conjugates of bis-pro-PBDs as well as folate conjugates of pro-PBD
hybrids with DNA minor groove binders, which employ cleavable
disulfide or enzyme –responsive self-immolative linker systems. In
addition, we will present the synthesis of novel folate-aminopterin
conjugates, which employ a series of cysteine-derived linkers,
which are reductively and/or enzymatically labile. Finally, we will
present structure activity relationship (SAR) data on a new series
of tubulysin analogs, and will detail the incorporation of one of
these analogs into a folate conjugate.”
Presentations are as follows:
Abstract # MEDI 87Title: Design and synthesis of N-alkylated
tubulysin analogs and their folate conjugatesWhen: Sunday, August
20, 2017 from 7:00 pm to 9:00 pm.Session ID: General Poster
SessionLocation: Walter E. Washington Convention Center
Room: Hall E
Abstract # MEDI 88Title: Pro-Pyrrolobenzodiazepine (pro-PBD)
bioconjugates, part 1: Design and synthesis of pro-PBD
conjugates containing a cleavable disulfide linkerWhen: Sunday,
August 20, 2017 from 7:00 pm to 9:00 pm.Session ID: General Poster
SessionLocation: Walter E. Washington Convention Center
Room: Hall E
Abstract # MEDI 90Title: Targeted folate-aminopterin
anti-inflammatory conjugates: Optimization of a
reductively/enzymatically labile cysteine-derived linker
systemWhen: Sunday, August 20, 2017 from 7:00 pm to 9:00 pm.Session
ID: General Poster SessionLocation: Walter E. Washington Convention
Center Room: Hall E
Abstract # MEDI 91Title: Pro-Pyrrolobenzodiazepine (pro-PBD)
bioconjugates, part 2: Design and synthesis of pro-PBD
conjugates containing an enzyme-responsive linkerWhen: Sunday,
August 20, 2017 from 7:00 pm to 9:00 pm.Session ID: General Poster
SessionLocation: Walter E. Washington Convention Center
Room: Hall E
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing
targeted therapies for the treatment of cancer and other serious
diseases. Endocyte uses its proprietary drug conjugation technology
to create novel SMDCs and companion imaging agents for personalized
targeted therapies. The company’s SMDCs actively target receptors
that are over-expressed on diseased cells relative to healthy
cells. This targeted approach is designed to enable the treatment
of patients with highly active drugs at greater doses, delivered
more frequently and over longer periods of time than would be
possible with the untargeted drug alone. The companion imaging
agents are designed to identify patients whose disease
over-expresses the target of the therapy and who are therefore more
likely to benefit from treatment. In addition, the company
continues to pursue applications of the SMDC platform and is
working to bring assets toward clinical development in several
areas, including EC2629, its dual-targeted DNA crosslinker drug
that can attack both TAMs and cancer cells, and its CAR T-Cell SMDC
adaptor platform. For additional information, please visit
Endocyte’s website at www.endocyte.com.
Contacts:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, stephanie@sternir.com
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Mar 2023 to Mar 2024